Search

Author/Creator Ambarkhane, S.

1. Long‐term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7‐year results from the PRECiSE 3 study. Issue 8 (22nd August 2014)

Authors:
Sandborn, W. J.; Lee, S. D.; Randall, C.; Gutierrez, A.; Schwartz, D. A.; Ambarkhane, S.; Kayhan, C.; Pierre‐Louis, B.; Schreiber, S.; Lichtenstein, G. R.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 40:Issue 8(2014)
Page Start:
903
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. L‐MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R‐R DLBCL) – A SINGLE‐ARM PHASE II STUDY. (June 2017)

Authors:
Salles, G.; González Barca, E.; Jurczak, W.; Liberati, A.M.; Duell, J.; Nagy, Z.; Papajík, T.; Andre, M.; Kalakonda, N.; Dreyling, M.; Zinzani, P.L.; Ambarkhane, S.; Weirather, J.; Maddocks, K.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
51
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. PRIMARY ANALYSIS RESULTS OF THE SINGLE‐ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (L‐MIND). (12th June 2019)

Authors:
Salles, G.; Duell, J.; González Barca, E.; Jurczak, W.; Liberati, A.M.; Nagy, Z.; Obr, A.; Gaidano, G.; Andre, M.; Kalakonda, N.; Dreyling, M.; Zinzani, P.L.; Dirnberger‐Hertweck, M.; Weirather, J.; Ambarkhane, S.; Maddocks, K.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
173
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗